Updated: Feb 24, 2020
Author: Julia R Nunley, MD; Chief Editor: Dirk M Elston, MD 



Calciphylaxis is a poorly understood and highly morbid syndrome of vascular calcification and skin necrosis. Bryant and White first reported it in association with uremia in 1898. However, the significance of this relationship became uncertain when vascular calcification was subsequently shown to be prevalent in uremia, yet the syndrome of vascular calcification with cutaneous necrosis was less common.[1]

In 1962, Selye[2] constructed an experimental model and was able to precipitate systemic calcification, somewhat analogous to this syndrome, in nephrectomized rats. He was the first to coin the term calciphylaxis to characterize this enigma. Over the years, many other names have been suggested to characterize the pathogenic process, which has remained elusive. Interestingly, the clinical importance of this syndrome was not recognized until a 1976 report by Gipstein et al.[3] Since then, a multitude of case reports of calciphylaxis have documented data outlining its morbidity and therapeutic dilemmas, as well as a quest to better understand its etiology and pathogenesis. Unfortunately, it remains a conundrum.[4]


The pathogenesis of calciphylaxis remains obscure and is likely the result of a multiplicity of comorbid factors or events. Disorders that are most often implicated in the pathogenesis of calciphylaxis include chronic renal failure, obesity, diabetes mellitus, hypercalcemia, hyperphosphatemia, an elevated calcium-phosphate product, secondary hyperparathyroidism, and a variety of hypercoagulable states. Yet, although these abnormalities are extremely common in patients with end-stage renal disease (ESRD), calciphylaxis is relatively rare.

Using a rat model, Selye[2] demonstrated that a series of events might be necessary for the formation of calciphylaxis. He defined calciphylaxis as a condition of hypersensitivity induced by a set of "sensitizing" agents, in which calcinosis occurred only in those subsequently subjected to a group of "challengers" and only after a critical lag time. Experimental sensitizing events and agents included nephrectomy and exposure to parathyroid hormone (PTH) and vitamin D. Substances used as challengers included egg albumin and metallic salts. Calciphylaxis was the end result.[5]

Although extrapolation of animal data to humans is conjectural, it seems to be true that serial events, most consistently involving renal failure–induced abnormalities in calcium homeostasis, are required to occur over time for calciphylaxis to develop. The cause of calciphylaxis has been elusive, most likely because it is the common endpoint of a heterogeneous group of disorders.

Many molecular and cytochemical factors have been identified as crucial in bone metabolism. The receptor activator of nuclear factor-kB (RANK), RANK ligand, and osteoprotegerin appear to regulate skeletal and extraskeletal mineralization.[6, 7] Uremia-induced defects in this system may predispose to calciphylaxis.[8] Corticosteroids, aluminum, hyperparathyroidism, liver disease, warfarin therapy, and a variety of inflammatory processes all can alter this balance and promote vascular calcification.[9, 10] Chronic inflammatory conditions may predispose to calciphylaxis by reducing serum levels of fetuin-A, an important inhibitor of calcification produced in the liver.[11, 12, 13] Other authors have recently suggested that calciphylaxis is an active form of osteogenesis with up-regulation of bone morphogenic protein 2 (BMP-2), Runx2, its target gene, and its indirect antagonist sclerostin.[14]

Most investigators note that the common endpoint of calciphylaxis is vascular occlusion and thrombosis, which results in cutaneous ischemia[15, 16, 17] ; however, the factors associated with thrombosis are not uniform.


Disorders associated with the development of calciphylaxis include the following[3, 6, 18, 19, 20] :

  • Common associations include chronic renal failure, hypercalcemia, hyperphosphatemia, elevated calcium-phosphate product, hyperparathyroidism, and vascular calcification.

  • Noted associations include aluminum toxicity, coagulation abnormalities, and iron dextran infusion.

  • Associations suggested from clinical observations include renal transplantation, immunosuppressive agents, corticosteroid use, and obesity.

  • Systemic inflammation appears to be a predisposing factor.[12, 13]

The cause of calciphylaxis remains obscure. Most cases occur in the setting of chronic renal failure, abnormal calcium-phosphate homeostasis, and hyperparathyroidism. Both hypercalcemia and hyperphosphatemia may be present, and the calcium-phosphate product frequently exceeds 60-70 mg2/dL2. However, calciphylaxis may occur in the setting of normal, or minimally elevated, calcium and phosphate levels.

Case reports exist of calciphylaxis occurring in primary hyperparathyroidism, cirrhosis, Crohn disease, malignancy, and rheumatoid arthritis, without renal disease. The pathogenesis of calciphylaxis in these cases is uncertain.[21, 18, 22, 23] The exact role of PTH is uncertain because calciphylaxis may occur after total parathyroidectomy, in the absence of measurable PTH levels.

Patients at an increased risk appear to be those who are obese and those who have been exposed to immunosuppressive agents, including glucocorticoids.[18] Calciphylaxis occurs more frequently in areas where body fat is most abundant, such as the thighs, the buttocks, and the lower part of the abdomen.[19, 20]  Fatty areas may be at higher risk for thrombosis, owing to lower blood flow, increased potential for vascular kinking, or more likely, involvement of adipocytes in the pathogenesis of calciphylaxis.[24]

Persons with diabetes mellitus may also be at an increased risk;[18, 19, 20] insulin injections may be an independent risk due to trauma to the subcutis.

The clinical appearance of the lesions of calciphylaxis (livedo reticularis and stellate purpura) suggests that the common endpoint of the process is small vessel occlusion. Indeed, microthrombi are found in most cases.

Hypercoagulable conditions, including protein C and protein S deficiencies, vitamin K deficiency, and the presence of a circulating anticoagulant have been described in a number of patients.[25, 26, 27, 28, 29, 24] However, conditions of hypercoagulability are not found uniformly. If they do exist, they could possibly precipitate or exacerbate calciphylaxis in a predisposed patient.

Vascular calcification is a constant finding in cases of calciphylaxis. Theoretically, various pathologic roles may be attributed to this vascular calcification. First, calcification of the vascular endothelium may alter the local interaction of procoagulant and anticoagulant factors, predisposing to a microenvironment of hypercoagulability. Alternatively, extensive endothelial calcification and intimal hyperplasia, which are known to compromise the luminal size of vessels in calciphylaxis, may result in vascular occlusion. Finally, data suggest that the uremic milieu may promote calcification through inhibition of various endogenous inhibitors of calcification such as alpha2-Heremans-Schmid glycoprotein/fetuin A (AHSG), osteopontin, and matrix Gla protein. These theories remain speculative.[8, 11]



Calciphylaxis is an uncommon condition that affects 1-4% of the population with ESRD.[30, 31] A concern exists that the incidence has increased during the last decade because of a number of possible factors, including more widespread use of parenteral vitamin D and iron dextran. No good data are available regarding the incidence of calciphylaxis in the general population without ESRD, but it is even less common. Nonuremic disease is being identified more commonly, especially in patients with rapid weight loss. Some cases are associated with warfarin use, but that association does not appear to alter prognosis.[32]


Although the disease may affect persons of any race, it appears to be more prevalent in whites.


Females are affected more often than males, with a female-to-male ratio of approximately 3:1. Females also appear to be more commonly affected with nonuremic calciphylaxis.


Calciphylaxis has been reported in individuals ranging in age from 6 months to 83 years. From a large series of patients, a mean patient age of 48 years (±16 y) has been calculated. Individuals seemingly more predisposed are younger patients who have had a longer duration of renal replacement therapy.


The prognosis is generally not good, with a mortality rate as high as 60-80% in patients with ulcerative disease.[9] The mortality rate is higher in patients with proximal disease than in those with only distal or acral disease. Patients who do not die of sepsis or organ failure frequently undergo amputation of an involved limb. Vascular calcification is theoretically reversible with aggressive management, but many patients have numerous comorbid diseases and intervention may be too late.[9] Currently, the 1- and 5-year survival rates are estimated to be 45% and 35%, respectively. A multidisciplinary approach with wound debridement, possible parathyroidectomy, and aggressive medical management may improve survival.[6] The impact of sodium thiosulfate on overall survival rate is yet to be determined.[33]

Patient Education

Emphasize compliance with the dialysis prescription. Educate patients regarding dietary restrictions and the need for phosphate binders. If anticoagulation is chosen, explain the risks and the benefits of this therapy.




Most patients with calciphylaxis have a long-standing history of chronic renal failure and renal replacement therapy. On rare occasions, calciphylaxis may occur in a patient with chronic renal failure prior to the initiation of replacement therapy. Very rarely, it may occur in an individual without a history of renal failure.

Many persons who develop calciphylaxis have undergone renal allograft transplantation. The allograft may still be functional when calciphylaxis develops. Frequently, patients have been noncompliant with dietary, medical, and/or dialysis prescriptions prior to the onset of calciphylaxis.

Lesions of calciphylaxis typically develop suddenly and progress rapidly. Lesions may be singular or numerous, and they generally occur on the lower extremities (see image below); however, lesions also may develop on the hands and torso. Intense pain is a constant finding, likely related to vascular ischemia and cutaneous infarction.

Several lesions of calciphylaxis that occurred on Several lesions of calciphylaxis that occurred on the lower extremity of a patient undergoing dialysis. These lesions developed in areas of livedo reticularis and followed the path of the vasculature.

The patient's history may reveal an event that is a suspected trigger or risk factor for the development of calciphylaxis. These triggers include the following[6, 9, 8, 21, 18, 19, 20, 24, 34, 35] :

  • Long-term obesity

  • Recent and sudden weight loss

  • Malnutrition

  • Gastric bypass surgery

  • Infusion of medications such as iron dextran

  • Remote and/or recent use of immunosuppressive agents, especially corticosteroids

  • Liver disease

  • Connective-tissue disease

  • Diabetes mellitus and insulin injections

  • Use of vitamin D and calcium-based phosphate binders

  • Elevated aluminum levels

  • Concomitant vascular disease

  • Systemic hypercoagulability

  • Vitamin K deficiency

  • Concurrent use of warfarin anticoagulation: Current data suggest that warfarin therapy may lower protein C concentrations, leading to a procoagulant condition in the calcified vessel. Warfarin may also inhibit carboxylation of matrix Gla protein, an important inhibitor of calcification, thus promoting calcification

Review of the patient's medical record usually reveals a history of hyperphosphatemia with hyperparathyroidism and hypoalbuminemia.[3] Patients with nonuremic calciphylaxis frequently have a history of primary hyperparathyroidism, malignancy, alcoholic liver disease, or underlying connective-tissue disease or pro-inflammatory condition.[21, 18, 22, 23, 36]

Physical Examination

Early lesions of calciphylaxis manifest as nonspecific violaceous mottling; as livedo reticularis; or as erythematous papules, plaques, or nodules. More developed lesions have a stellate purpuric configuration with central cutaneous necrosis (see the image below).

An isolated lesion of calciphylaxis manifesting as An isolated lesion of calciphylaxis manifesting as an enlarging necrotic plaque on the lower extremity of a patient undergoing dialysis. The stellate purpuric morphology can be appreciated surrounding the area of necrosis.

Multiple lesions of variable age may be present, following the path of the vasculature. Less commonly, lesions may manifest as either bullae (see the image below) or distinct subcutaneous, erythematous nodules suggestive of erythema nodosum. Lesions are excruciatingly tender and extremely firm.

Calciphylaxis may manifest as rapidly progressive, Calciphylaxis may manifest as rapidly progressive, diffuse and extensive, cutaneous necrosis, as is seen in this patient with chronic renal failure. Bullae may also be seen as a rare manifestation of calciphylaxis.

The distribution of the lesions may be characterized as proximal or distal. Ninety percent of lesions of calciphylaxis occur on the lower extremities. Distal lesions are those that occur below the knee; proximal lesions occur on the thighs or the trunk. Proximally distributed lesions occur in 44-68% of patients, with lesions developing predominantly on the thighs, the buttocks, and the lower part of the abdomen. Distal and visceral involvement are not uncommon.

An intact peripheral pulse helps to distinguish acral calciphylaxis from atherosclerotic peripheral vascular disease. Ulceration is considered a late finding and is associated with a higher mortality rate.


Complications of calciphylaxis range from moderate interference with activity to death. Lesions of calciphylaxis frequently result in nonhealing ulcers and cutaneous gangrene. Acral lesions may fail to heal with conservative therapy and lead to amputation. Sepsis may result from the nonhealing wounds.

Patients with internal involvement may develop gastrointestinal hemorrhage, infarction, or organ failure.

Patients treated with calcimimetics, sodium thiosulfate, and parathyroidectomy must be monitored for hypocalcemia. Those on sodium thiosulfate should be monitored for metabolic acidosis.





Laboratory Studies

Consider the following laboratory tests and results:

  • Serum blood urea nitrogen and creatinine levels

  • Serum calcium, phosphate, alkaline phosphatase, and albumin levels

  • Serum parathyroid hormone (PTH) level

  • Coagulation factors - Prothrombin time, activated partial thromboplastin time, antithrombin III, protein C level, protein S level, anticardiolipin level, lupus anticoagulant level, factor V Leiden level, and homocysteine level

  • Cryoglobulin and rheumatoid factor measurements

  • Hepatitis C antibody level

  • Cryofibrinogen level

  • Serum amylase and lipase level

  • Aluminum level

  • Measures of inflammation - Erythrocyte sedimentation rate and C-reactive protein value

  • To exclude underlying vasculitis - Antineutrophilic antibody (ANA), antineutrophil cytoplasmic antibodies (ANCA)

Imaging Studies

Plain radiography uniformly demonstrates an arborization of vascular calcification within the dermis and the subcutaneous tissue (see the image below). Although calcification is common in persons with end-stage renal disease, and not specific for calciphylaxis, a recent study showed patients with calciphylaxis had more vascular calcifications, more small vessel calcifications, and a netlike pattern of calcifications. This netlike pattern, when present, was strongly associated with the presence of calciphylaxis.[37]

Radiologic findings of a hand in a patient with ca Radiologic findings of a hand in a patient with calciphylaxis. Extensive calcification of the radial and ulnar arteries is readily visible.

Bone scintigraphy may be used as a noninvasive diagnostic tool because the bone matrix protein osteopontin has recently been demonstrated in calciphylaxis lesions.[38] Serial bone scanning can also possibly be used to monitor progression or regression of disease.[39, 40]


Punch biopsies may not be adequate because the quantity or depth of tissue obtained may not be enough for diagnosis. An incisional cutaneous biopsy is usually diagnostic.[41] Ample subcutaneous tissue must be available for adequate evaluation.

The decision to perform a biopsy on a nonulcerated lesion should not be made lightly because it could result in a nonhealing wound. Although lesions of calciphylaxis have a clinical appearance suggestive of avascular necrosis, the tissue often bleeds freely during surgery. Furthermore, lesional ulceration increases the mortality rate 2-fold.

Histologic Findings

Biopsy specimens typically demonstrate calcification within the media and intima of small- and medium-sized arterioles with extensive intimal hyperplasia and fibrosis, but this also may be seen in uninvolved skin in patients with chronic kidney disease or atherosclerosis.[42] A mixed inflammatory infiltrate frequently occurs. Subcutaneous calcium deposits with panniculitis and fat necrosis may sometimes be found. Vascular microthrombi are frequently evident. See the image below.

Calcification of capillaries within the subcutaneo Calcification of capillaries within the subcutaneous fat, characteristic of calciphylaxis. Image courtesy of Dirk Elston, MD.


Medical Care

Therapy is multifaceted and includes medical and surgical intervention.[43, 44] Aggravating conditions should be addressed, and trigger factors should be eliminated. This may mean the discontinuation of parenteral iron therapy, calcium supplementation, and vitamin D supplementation. Cessation of warfarin therapy should be considered. Although frequently implicated as a trigger some studies suggest that patients may benefit from systemic glucocorticoids early on, unless ulcerated lesions are present. Early use of sodium thiosulfate should be considered.[45, 46]

In patients with an elevated calcium-phosphate product, serum calcium and phosphate concentrations must be brought to low-normal levels as quickly and safely as possible.[47, 48] Conservative therapy should be tried first, with dietary alteration, use of noncalcium, nonaluminum phosphate binders and low-calcium bath dialysis.[49] Some benefit may be achieved with increasing the frequency or duration of dialysis sessions.

Calcimimetics such as cinacalcet hydrochloride may be beneficial in cases of hyperparathyroidism.[50, 51, 52] These agents increase the sensitivity of the calcium receptors to available calcium, thereby decreasing PTH secretion. Studies have shown efficacy in decreasing PTH, calcium, and phosphate levels. Reports of successful treatment with these agents as adjunctive therapy for calciphylaxis are emerging.[53, 54]

Bisphosphonates (eg, pamidronate,[55, 56] etridronate[57] ) increase osteoprotegerin production and inhibit arterial calcification. Case reports suggest these may be helpful in some cases of calciphylaxis, even without changing calcium or phosphate levels.[53, 58, 59, 60] Parathyroidectomy should be considered if conservative management fails, but only if hyperparathyroidism is present.

Marked improvement of calciphylaxis has now been reported with the use of intravenous sodium thiosulfate. Sodium thiosulfate is a potent antioxidant, and it also increases the solubility of calcium deposits. Success has been reported in uremic and nonuremic calciphylaxis.[8, 53, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70]

Calciphylaxis therapy with sodium thiosulfate is off-label usage, but reports of success are mounting. A study of 14 patients suggests that several factors may impact patient outcome.[71] Earlier intervention and/or a higher total dose of sodium thiosulfate may be more effective but more poorly tolerated. More obese patients and patients on long-term renal replacement therapy did not fair as well. Success was recently reported in a nonuremic patient treated with intravenous sodium thiosulfate.[72] A multimodality approach using sodium thiosulfate, cinacalcet, and sevelamer has also been used.[73]

Sodium thiosulfate has been administered intravenously, intralesionally, or topically; intraperitoneal administration is not recommended owing to the risk of chemical peritonitis.[24] Sodium thiosulfate has been used in both adults and children.[74] Intravenous doses have varied from 5-75 g after or during hemodialysis in adults. The most commonly reported dose has been 25 g after each dialysis. Some have used weight-based dosing (especially in children) at using 12 g/1.7 m2. Infusion times vary from 30-60 minutes. Although generally well tolerated, adverse effects have include nausea with emesis and the development of an anion gap metabolic acidosis that can be managed by altering the bicarbonate level of the dialysate. Symptomatic relief and clinical improvement may occur within 2 weeks. See the Anion Gap calculator.

Early data suggest that intralesional sodium thiosulfate may also be an option.[75]

Patients should be monitored for the potential development of a metabolic acidosis. Oral sodium thiosulfate has also been reported to suppress calciphylaxis, although oral absorption may be poor. A 2 M (molar) solution can be prepared with 74.4 g in 150 mL free water; 2.6 g can be given orally daily or 3 times a week. Dose is limited by diarrhea.

Judicious use of antibiotics may be advantageous. Additionally, in some cases, hyperbaric oxygen may be beneficial to promote wound healing.[76, 77]

Conditions of hypercoagulability should be sought and addressed. Patients with documented conditions of hypercoagulability may benefit from proper and adequate anticoagulation.[78] Successful treatment of calciphylaxis with low-dose tissue plasminogen activator has been reported.[79] Laboratory evaluation of the reported patient demonstrated low antithrombin III antigen and activity, as well as low protein C antigen and activity prior to intervention with tissue plasminogen activator therapy. However, the role of anticoagulation in all cases of calciphylaxis is controversial. Random prophylactic use of warfarin or heparin is not indicated because precipitation of calciphylaxis has occurred with its use.[80, 81] In addition, most patients with ESRD have a prolonged bleeding time due to the uremic condition, and anticoagulation or tissue plasmogen activator therapy should be approached cautiously. Nonetheless, in the setting of thrombotic occlusion and cutaneous ischemia, restoration of blood flow is critical.[15] Although the anticoagulant of choice in a dialysis patient is up for debate, the two best options are most likely unfractionated heparin, and apixaban, a factor Xa inhibitor.[24]

Studies are ongoing regarding the effectiveness of vitamin K supplementation.[24]

Studies are also ongoing regarding the use of intravenous SNF472, a myoinositol hexaphosphate, that binds to calcium hydroxyapatite crystals within blood vessels, inhibiting further growth.[24]

Pain management is also crucially important.[82] Consultation with pain-management specialists may be necessary.

Surgical Care

Aggressive wound care and debridement of necrotic tissue may be necessary to avoid wound infection and sepsis.[6] However, some advise against debridement. Currently, there is no consensus on wound management.[17] The decision to debride, and to what extent, depends on the patient's overall health and the clinical picture.

Use of a vacuum-assisted closure device has been successful in several cases of calciphylaxis after extensive debridement and prior to skin grafting.[83]

Total or subtotal parathyroidectomy with autotransplantation may be of therapeutic benefit.[6, 49, 84, 85, 86]  Small case studies have demonstrated some benefit; however, other larger retrospective studies have shown no significant difference in survival.[17] Decisions should be made on a case-to-case basis.


Consult a surgeon regarding wound debridement and possible parathyroidectomy. Consult a dietitian regarding dietary alterations. Consider consulting a pain-management specialist.


Patients with abnormalities in calcium and phosphate homeostasis need to be referred to a dietitian well versed in the dietary needs and restrictions of patients with ESRD. Special consideration should be given to phosphate restriction.


The patient's activity may be greatly hampered by the pain and the ulceration of calciphylaxis lesions. Patients are generally hospitalized in intensive care units during the acute illness.


Questions & Answers


What is calciphylaxis?

What is the historical importance of calciphylaxis?

What is the pathogenesis of calciphylaxis?

What molecular and chemical factors are involved in the pathophysiology of calciphylaxis?

Which disorders are associated with the development of calciphylaxis?

What causes calciphylaxis?

Which patients are at an increased risk for calciphylaxis?

What do the lesions of calciphylaxis (livedo reticularis and stellate purpura) suggest?

What is the role of hypercoagulable conditions in the etiology of calciphylaxis?

What is the role of vascular calcification in the etiology of calciphylaxis?

What is the prevalence of calciphylaxis?

What are the racial predilections for calciphylaxis?

How does the prevalence of calciphylaxis vary by sex?

How does the prevalence of calciphylaxis vary by age?

What is the prognosis of calciphylaxis?

What is included in patient education about calciphylaxis?


Which clinical history is characteristic of calciphylaxis?

What are risk factors for the development of calciphylaxis?

What should be the focus of history in suspected calciphylaxis?

What are the physical findings characteristic of calciphylaxis?

What are potential complications of calciphylaxis?


What should be included in the differential diagnoses for calciphylaxis?

What are the differential diagnoses for Calciphylaxis?


Which lab tests are performed in the workup of calciphylaxis?

What is the role of imaging studies in the workup of calciphylaxis?

What is the role of biopsy in the workup of calciphylaxis?

Which histologic findings are characteristic of calciphylaxis?


What is the initial therapy for calciphylaxis?

What are the treatment options for patients with an elevated calcium-phosphate product and calciphylaxis?

What is the role of calcimimetics in the treatment of calciphylaxis?

What is the role of bisphosphonates in the treatment of calciphylaxis?

What is the role of sodium thiosulfate in the treatment of calciphylaxis?

How should patients with calciphylaxis be monitored?

What is the role of antibiotics in the treatment of calciphylaxis?

How are hypercoagulability conditions managed in patients with calciphylaxis?

How is pain managed in calciphylaxis?

What is the role of surgery in the treatment of calciphylaxis?

Which specialist consultations may be considered in the treatment of calciphylaxis?

Which dietary restrictions are needed in the treatment of calciphylaxis?

How should activity be restricted during the treatment of calciphylaxis?